Malignant immunoproliferative diseases (controls excluding all cancers)

PheWeb

CD2_IMMUNOPROLIFERATIVE_EXALLC

No definition available.

Endpoint definition

↥

FinnGen phenotype data

individuals

Apply sex-specific rule None

Check conditions None

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 C88

Cause of death: ICD-10 C88

2 out of 7 registries used, show all original rules.

Check minimum number of events None

Include endpoints None

Remove individuals based on genotype QC

223

CD2_IMMUNOPROLIFERATIVE_EXALLC

Control definitions

Control exclude C3_CANCER

Extra metadata

Level in the ICD hierarchy 3

First used in FinnGen datafreeze DF4

Parent code in ICD-10 C81-C96

Name in latin Morbi immunoproliferativi maligni

NAME	CD2_IMMUNOPROLIFERATIVE_EXALLC
CONTROL_EXCLUDE	C3_CANCER
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	C88
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	C88
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Show upset plot detailing case counts by codes

Or the full data table

Similar endpoints

↥

List of similar endpoints to Malignant immunoproliferative diseases (controls excluding all cancers) based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

Malignant immunoproliferative diseases

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	223	94	129
Unadjusted prevalence (%)	0.06	0.04	0.08
Mean age at first event (years)	66.43	64.81	67.61

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: CD2_IMMUNOPROLIFERATIVE_EXALLC – Malignant immunoproliferative diseases (controls excluding all cancers)
GWS hits: 1

Survival analyses between endpoints

↥

Plot

before Malignant immunoproliferative diseases (controls excluding all cancers)
after Malignant immunoproliferative diseases (controls excluding all cancers)

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Malignant immunoproliferative diseases (controls excluding all cancers)

↥

Endpoint not on priority list, no data to show.

≡ Risteys

R9

R8

R7

R6

R5

R4

R3